Skip to main content

Table 2 Baseline and follow-up characteristics of rheumatoid factor and antibodies against CCP isotypes for responders and non-responders to RTX, respecting baseline seropositivity, mean titers and their relative changes upon RTX treatment

From: Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis

50 RA patients upon RTX treatment RRs (n = 37) NRRs (n = 13)
  RF IgG
Positive at baseline (n, %) 2 5 % 1 8 %
Negative at baseline (n, %) 35 95 % 12 92 %
Mean baseline titer (v ± SD in IU/ml) 11.99 15.99 13.69 12.30
Titer decrease (n, %) 37 100 % 13 100 %
Titer increase (n, %) 0 0 % 0 0 %
Mean titer at 24 weeks (v ± SD in IU/ml) 3.07 0.97 4.47 3.48
Percentage decline/Wilcoxon P value 74.38 % P <0.0001 67.32 % P = 0.002
Mann–Whitney U P value (24 weeks) P = 0.224
Seronormalization (n, %) 2 100 % 1 100 %
Seroconversion (n, %) 0 0 % 0 0 %
  RF IgM
Positive at baseline (n, %) 21 57 % 8 62 %
Negative at baseline (n, %) 16 43 % 5 38 %
Mean baseline titer (v ± SD in IU/ml) 44.48 69.40 86.22 102.8
Titer decrease (n, %) 36 97 % 11 85 %
Titer increase (n, %) 0 0 % 2 15 %
Mean titer at 24 weeks (v ± SD in IU/ml) 16.54 20.85 58.67 81.14
Percentage decline/Wilcoxon P value 62.82 % P <0.0001 31.95 % P = 0.011
Mann–Whitney U P value (24 weeks) P = 0.170
Seronormalization (n, %) 8 38 % 1 13 %
Seroconversion (n, %) 0 0 % 0 0 %
  RF IgA
Positive at baseline (n, %) 20 54 % 9 69 %
Negative at baseline (n, %) 17 46 % 4 31 %
Mean baseline titer (v ± SD in IU/ml) 102.35 124.7 167.6 144.7
Titer decrease (n, %) 30 81 % 10 77 %
Titer increase (n, %) 5 14 % 2 15 %
Mean titer at 24 weeks (v ± SD in IU/ml) 60.77 94.57 124.0 128.4
Percentage decline/Wilcoxon P value 40.62 % P <0.0001 26.05 % P = 0.014
Mann–Whitney U P value (24 weeks) P = 0.147
Seronormalization (n, %) 7 35 % 1 11 %
Seroconversion (n, %) 1 6 % 0 0 %
  ACCP IgG
Positive at baseline (n, %) 34 92 % 12 92 %
Negative at baseline (n, %) 3 8 % 1 8 %
Mean baseline titer (v ± SD in U/ml) 1125.71 700.0 1044.35 775.6
Titer decrease (n, %) 29 78 % 8 62 %
Titer increase (n, %) 5 14 % 4 31 %
Mean titer at 24 weeks (v ± SD in U/ml) 841.11 667.2 861.55 682.1
Percentage decline/Wilcoxon P value 25.28 % P <0.0001 17.50 % P = 0.129
Mann–Whitney U P value (24 weeks) P = 0.982
Seronormalization (n, %) 0 0 % 0 0 %
Seroconversion (n, %) 0 0 % 0 0 %
  1. ACCP, antibodies against cyclic citrullinated peptide; n, number of patients; NRRs, non-responders to RTX; RF, rheumatoid factor; RRs responders to RTX; RTX, rituximab; SD, standard deviation; v, value